Effects of ulinastatin therapy in deep vein thrombosis prevention after brain tumor surgery: A single-center randomized controlled trial

Table 2 Comparison of baseline data between two venous thromboembolism group patients, n (%)

VTE Patients	UTI group (n = 15)	Placebo group (n = 28)	P value
Age (yr, mean ± SD)	59.9 ± 8.1	59.4 ± 8.5	0.853
Gender			0.782
Male	9 (60.00)	18 (64.29)
Female	6 (40.00)	10 (35.71)
BMI (kg/cm2, mean ± SD)	22.4 ± 2.5	22.1 ± 2.4	0.702
Smoking History			0.598
Yes	10 (66.67)	19 (67.86)
No	5 (33.33)	9 (32.14)
Living environment			0.702
Town	13 (72.22)	23 (82.14)
Countryside	2 (27.78)	5 (17.86)
Past medical history
Hypertension	8 (53.33)	15 (53.57)	0.988
Hyperlipidemia	8 (53.33)	12 (42.86)	0.512
Diabetes	7 (46.67)	13 (46.43)	0.988
Cholelithiasis	6 (40.00)	10 (35.71)	0.782
Brain tumor type			0.484
Benign tumor	8 (53.33)	18 (64.29)
Malignant tumor	7 (46.67)	10 (35.71)
Surgery time (h, mean ± SD)	4.7 ± 1.7	4.6 ± 1.5	0.843

BMI: Body mass index; UTI: Ulinastatin; VTE: Venous thromboembolism.